Prime Highlights
- Meiji Seika Pharma invested in the Global Health Security Fund.
- The fund supports pandemic and disease-preparedness technologies.
Key Facts
- GHSF has secured $353 million in commitments.
- GHIC and BARDA established the fund.
Background
The company Meiji Seika Pharma is expected to participate in investing in the Global Health Security Fund (GHSF), which will allow the company to focus on the issue of global health security. As a result of such investments, the company Meiji Seika Pharma will be able to work on creating technologies and products that can contribute to overcoming possible challenges related to infectious diseases.
This information was announced in the beginning of June 2026 in Tokyo. Through the investment, Meiji Seika Pharma intends to increase its participation in healthcare innovations in a manner that will make an effort to boost the ability to prevent, diagnose, and treat different diseases around the world.
The Global Health Security Fund was launched following an agreement between GHIC and the Biomedical Advanced Research and Development Authority (BARDA) in the United States.
GHIC recently completed fundraising for the Global Health Security Fund, securing $353 million in commitments from public and private sector investors. Participants include pharmaceutical companies, healthcare organisations and research institutions involved in vaccines, diagnostics, therapeutics and biotechnology.
The investment reflects growing interest in health-security technologies following recent global disease outbreaks. Industry experts believe governments and healthcare companies are placing greater emphasis on preparedness and rapid response capabilities to manage future health emergencies.
According to GHIC, companies within its investment portfolio have already launched more than a dozen healthcare products that have reached over 600 million people globally. The organisation has spent more than a decade supporting innovation in infectious disease technologies and public health solutions.
Meiji Seika Pharma said the partnership aligns with its long-standing focus on vaccines, infectious disease treatment and healthcare research. The company plans to use the collaboration to strengthen research and development efforts and address unmet medical needs.
The fund is expected to continue supporting companies developing vaccines, diagnostics, manufacturing technologies and other healthcare solutions that enhance global preparedness for future public health crises.
